GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.16 CNY | -1.94% |
|
-0.07% | -5.55% |
| 22/04 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 11/03 | Zhongsheng Pharma's Chairman to Raise Stake in Company | MT |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
Weaknesses
- With an expected P/E ratio at 32.26 and 29.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.55% | 1.78B | - | C | |
| +30.38% | 684B | C+ | ||
| +26.51% | 568B | B | ||
| -4.36% | 361B | C+ | ||
| +19.30% | 329B | B- | ||
| +3.73% | 284B | C+ | ||
| +16.70% | 240B | B+ | ||
| +8.78% | 208B | B- | ||
| -7.93% | 200B | A+ | ||
| +7.68% | 166B | C+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002317 Stock
- Ratings Guangdong Zhongsheng Pharmaceutical Co., Ltd.
